Working… Menu

Double-Blind Lamictal (Lamotrigine) in Neurotic Excoriation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00513019
Recruitment Status : Completed
First Posted : August 8, 2007
Results First Posted : September 27, 2013
Last Update Posted : September 27, 2013
Information provided by (Responsible Party):
Jon Grant, University of Chicago

Brief Summary:
The goal of the proposed study is to evaluate the comparative efficacy of Lamictal (lamotrigine) to placebo in neurotic excoriation. Thirty subjects with neurotic excoriation will receive 12 weeks of double-blind treatment with Lamictal (lamotrigine) or matching placebo. The hypothesis to be tested is that Lamictal (lamotrigine) will be more effective than placebo in patients with neurotic excoriation. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.

Condition or disease Intervention/treatment Phase
Neurotic Excoriation Pathologic Skin Picking Psychogenic Excoriation Dermatillomania Drug: Lamictal (lamotrigine) Drug: Placebo Phase 2

Detailed Description:
The study will consist of 12 weeks of double-blind treatment with Lamictal (lamotrigine) compared to placebo (1:1) in 30 subjects with neurotic excoriation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 35 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blind Study of Lamictal in Neurotic Excoriation
Study Start Date : August 2007
Actual Primary Completion Date : August 2009
Actual Study Completion Date : September 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Lamotrigine

Arm Intervention/treatment
Active Comparator: 1
Lamictal (lamotrigine)
Drug: Lamictal (lamotrigine)
once daily from beginning to end of study. Dosage varies.
Other Name: lamotrigine

Placebo Comparator: 2
Drug: Placebo

Primary Outcome Measures :
  1. The Yale-Brown Obsessive Compulsive Scale Modified for Neurotic Excoriation (NE-YBOCS) Will be the Primary Outcome Measure [ Time Frame: beginning and at each visit until the end of their participation in the study (12-weeks); investigator rated. Note: Reported mean and standard deviation is the final reported data point. ]
    The Yale-Brown Obsessive Compulsive Scale Modified for Neurotic Excoriation (NE-YBOCS) was the primary outcome measure - severity of illness. The NE-YBOCS is a reliable and valid, 10-item, clinician-administered scale that rates buying symptoms within the last seven days, on a severity scale from 0 to 4 for each item (total scores range from 0 to 40 with higher scores reflecting greater illness severity).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. men and women age 18-65;
  2. current diagnosis of neurotic excoriation.

Exclusion Criteria:

  1. unstable medical illness or clinically significant abnormalities on prestudy laboratory tests or physical examination;
  2. history of seizures;
  3. myocardial infarction within 6 months;
  4. current pregnancy or lactation, or inadequate contraception in women of childbearing potential;
  5. a need for medication other than Lamictal with possible psychotropic effects or unfavorable interactions with Lamictal;
  6. clinically significant suicidality;
  7. lifetime history of DSM-IV bipolar disorder type I, dementia, or schizophrenia or any other DSM-IV psychotic disorder;
  8. current or recent (past 3 months) DSM-IV substance abuse or dependence;
  9. illegal substance use within 2 weeks of study initiation;
  10. initiation of psychotherapy or behavior therapy from a mental health professional within 3 months prior to study baseline;
  11. previous treatment with Lamictal (lamotrigine);
  12. treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline;
  13. current treatment with an anti-epileptic medication.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00513019

Layout table for location information
United States, Minnesota
Ambulatory Research Center
Minneapolis, Minnesota, United States, 55454
Sponsors and Collaborators
University of Chicago
Layout table for investigator information
Principal Investigator: Jon E Grant, M.D. University of Minnesota
Layout table for additonal information
Responsible Party: Jon Grant, Professor of Psychiatry, University of Chicago Identifier: NCT00513019    
Other Study ID Numbers: 0703M03384
First Posted: August 8, 2007    Key Record Dates
Results First Posted: September 27, 2013
Last Update Posted: September 27, 2013
Last Verified: August 2013
Keywords provided by Jon Grant, University of Chicago:
Neurotic Excoriation
Pathologic Skin Picking
Psychogenic Excoriation
Additional relevant MeSH terms:
Layout table for MeSH terms
Self-Injurious Behavior
Skin Diseases
Behavioral Symptoms
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Sodium Channel Blockers